



Beta-Site APP Cleaving Enzyme 2 (bACE2) Antibody

Catalogue No.:abx032689







Cerebral deposition of amyloid beta peptide is an early and critical feature of Alzheimer's disease and a frequent complication of Down syndrome. Amyloid beta peptide is generated by proteolytic cleavage of amyloid precursor protein by 2 proteases, one of which is the protein encoded by bACE2. This gene localizes to the 'Down critical region' of chromosome 21. The encoded protein, a member of the peptidase A1 protein family, is a type I integral membrane glycoprotein and aspartic protease.

Target: Beta-Site APP Cleaving Enzyme 2 (bACE2)

Clonality: Polyclonal

Reactivity: Human

Tested Applications: ELISA, WB, FCM

Host: Rabbit

Recommended dilutions: WB: 1/1000, FCM: 1/10 - 1/50. Optimal dilutions/concentrations should be determined by the end

user.

Conjugation: Unconjugated

Immunogen: KLH-conjugated synthetic peptide between 336-365 amino acids from the Central region of human

BACE2.

Isotype: IgG

1 of 2

Datasheet

Version: 3.0.0 Revision date: 05 Oct 2025



Form: Liquid

Purification: Purified through a protein G column, eluted with high and low pH buffers and neutralized

immediately, followed by dialysis against PBS.

Storage: Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

UniProt Primary AC: Q9Y5Z0 (UniProt, ExPASy)

String: <u>9606.ENSP00000332979</u>

Molecular Weight: Calculated MW: 56.2 kDa

Buffer: PBS containing 0.09% sodium azide.

Note: THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC,

THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL

CONSUMPTION.

Website: www.abbexa.com · Email: info@abbexa.com